Xin Lang Cai Jing·2026-03-05 02:18Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a rebound, particularly in innovative drug companies, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3% after a five-day decline, indicating increased investor interest despite recent lows [1][8]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and is currently up over 3%, recovering from a historical low reached after five consecutive days of decline [1][8]. - The ETF has seen a net inflow of over 135 million yuan in the past five days, suggesting a strategic accumulation by investors [1][8]. - The Hong Kong medical sector ETF (159137) also opened higher, with significant contributions from major stocks like WuXi Biologics and BeiGene, indicating a broader market recovery [3][10]. Group 2: Company Developments - China National Pharmaceutical Group's stock surged over 5% following the announcement of an exclusive licensing agreement with Sanofi for a drug, which includes an upfront payment of $135 million and potential milestone payments totaling up to $1.395 billion [1][10]. - The innovative drug business development (BD) in China surpassed $50 billion in the first two months of 2026, with upfront payments nearing $3 billion, highlighting a significant growth trend in the sector [3][10]. - Companies like Rongchang Biologics and Junshi Biosciences are transitioning to profitability, with Rongchang expected to report a net profit of 709 million yuan in 2025 [3][10]. Group 3: Investment Opportunities - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds are positioned as efficient investment vehicles for those looking to capitalize on the innovative drug sector, with over 70% of the top ten holdings being leading companies [5][12]. - The Hong Kong medical ETF (159137) encompasses a wide range of innovative medical concepts, including brain-computer interfaces and AI healthcare, providing diverse investment opportunities [6][12].